Five-year overall survival (OS) and OS by baseline liver function from the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

被引：0

作者：

Kudo, M. ^{[1
]}

Rimassa, L. ^{[2
]}

Chan, S. L. ^{[3
]}

Sangro, B. ^{[4
,5
,6
]}

Lau, G. ^{[7
]}

Breder, V. V. ^{[8
]}

Varela, M. ^{[9
]}

Crysler, O. V. ^{[10
]}

Bouattour, M. ^{[11
]}

Dao, V. T. ^{[12
]}

Faccio, A. ^{[13
]}

Furuse, J. ^{[14
]}

Jeng, L-B. ^{[15
]}

Kang, Y-K. ^{[16
]}

Kelley, R. K. ^{[17
]}

Paskow, M. J. ^{[18
]}

Makowsky, M. ^{[19
]}

Ran, D. ^{[20
]}

Negro, A. ^{[19
]}

Abou-Alfa, G. K. ^{[21
,22
]}

机构：

[1] Kindai Univ, Fac Med, Dept Gastroenterol & Hepatol, Osaka, Japan

[2] Humanitas Univ, Pieve Emanuele & Humanitas Canc Ctr, IRCCS Humanitas Res Hosp, Dept Biomed Sci, Milan, Italy

[3] Chinese Univ Hong Kong, State Key Lab Translat Oncol, Dept Clin Oncol, Sir Yue Kong Pao Ctr Canc, Hong Kong, Peoples R China

[4] Clin Univ Navarra, Liver Unit, Pamplona, Spain

[5] Clin Univ Navarra, HPB Oncol Area, Pamplona, Spain

[6] CIBEREHD, Pamplona, Spain

[7] Humanity & Hlth Med Grp, Humanity & Hlth Clin Trial Ctr, Hong Kong, Peoples R China

[8] NN Blokhin Natl Med Res Ctr Oncol, Dept Chemotherapy, Moscow, Russia

[9] Univ Oviedo, Liver Unit, Hosp Univ Cent Asturias, IUOPA,ISPA,FINBA, Oviedo, Spain

[10] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI USA

[11] Hop Beaujon, AP HP, Liver Canc Unit, Paris, France

[12] Natl Canc Hosp, Canc Res & Clin Trials Ctr, Dept Optimal Therapy, Hanoi, Vietnam

[13] CEON Ctr Especializado Oncol, Dept Oncol, Ribeirao Preto, Brazil

[14] Kanagawa Canc Ctr, Dept Gastroenterol, Tokyo, Japan

[15] China Med Univ & Hosp, Dept Surg, Taichung, Taiwan

[16] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea

[17] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[18] AstraZeneca, Global Med Affairs, Gaithersburg, MD USA

[19] AstraZeneca, Oncol R&D, Late Stage Dev, Gaithersburg, MD USA

[20] AstraZeneca, Stat, Gaithersburg, MD USA

[21] Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[22] Cornell Univ, Weill Med Coll, New York, NY USA

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.10.151

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1270

引用

页码：S1451 / S1452

页数：3

共 50 条

[21] Patient-Reported Outcomes From the Phase III HIMALAYA Study of Tremelimumab Plus Durvalumab in Unresectable Hepatocellular Carcinoma
Sangro, Bruno
Galle, Peter R.
Kelley, Robin Kate
Charoentum, Chaiyut
De Toni, Enrico N.
Ostapenko, Yurii
Heo, Jeong
Cheng, Ann-Lii
Woods, Andrea Wilson
Gupta, Charu
Abraham, Jayne
Mccoy, Carrie L.
Patel, Nikunj
Negro, Alejandra
Vogel, Arndt
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23)
[22] Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
Lau, George
Abou-Alfa, Ghassan K.
Cheng, Ann-Lii
Sukeepaisarnjaroen, Wattana
Kang, Yoon Koo
Dao, Tu Van
Thungappa, Satheesh Chiradoni
Kudo, Masatoshi
Sangro, Bruno
Kelley, Robin Kate
Furuse, Junji
Park, Joong-Won
Sunpaweravong, Patrapim
Fasolo, Angelica
Yau, Thomas
Kawaoka, Tomokazu
Azevedo, Sergio
Reig, Maria
Assenat, Eric
Yarchoan, Mark
He, Aiwu Ruth
Makowsky, Mallory
Gupta, Charu
Negro, Alejandra
Chan, Stephen L.
JOURNAL OF HEPATOLOGY, 2025, 82 (02)
[23] Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
Lau, George
Sangro, Bruno
Crysler, Oxana V.
Sukeepaisarnjaroen, Wattana
Lipatov, Oleg
Morimoto, Manabu
Archambeaud, Isabelle
Burgio, Valentina
Phuong, Le Thi Tuyet
Chao, Yee
Peron, Jean-Marie
Berres, Marie-Luise
Ko, Yoo-Joung
Mccoy, Carrie L.
Gupta, Charu
Makowsky, Mallory
Negro, Alejandra
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[24] Outcomes by occurrence of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
Lau, George
Cheng, Ann-Lii
Sangro, Bruno
Kudo, Masatoshi
Kelley, Robin Kate
Tak, Won Young
Gasbarrini, Antonio
Reig, Maria
Lim, Ho Yeong
Tougeron, David
De Toni, Enrico N.
Tam, Vincent C.
Mody, Kabir
Gong, Jun
Mccoy, Carrie L.
Gupta, Charu
Makowsky, Mallory
Negro, Alejandra
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[25] Adverse Event Profiles and Time to Onset and Resolution with Tremelimumab ( T) plus Durvalumab (D) in Patients with Unresectable Hepatocellular Carcinoma (uHCC) in the Phase 3 HIMALAYA Trial
De Toni, E. M.
Sangro, B.
Chan, S. L.
Kudo, M.
Kelley, R. K.
-K, Kang Y.
Rimassa, L.
Varela, M.
Dayyani, F.
Makowsky, M.
Marcovitz, M.
Mccoy, C. L.
Negro, A.
Abou-Alfa, G.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 239 - 240
[26] Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC)
Vogel, Arndt
Frenette, Catherine
Sung, Max W.
Daniele, Bruno
Baron, Ari David
Chan, Stephen Lam
Blanc, Jean-Frederic
Tamai, Toshiyuki
Ren, Min
Lim, Howard John
Palmer, Daniel H.
Takami, Yuko
Kudo, Masatoshi
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
[27] Patient-reported outcomes from the phase 3 HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro, Bruno
Galle, Peter R.
Kelley, Robin Kate
Charoentum, Chaiyut
De Toni, Enrico N.
Ostapenko, Yuriy
Heo, Jeong
Cheng, Ann-Lii
Vogel, Arndt
Marcovitz, Michelle
Abraham, Jayne
Patel, Nikunj
Negro, Alejandra
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[28] NON-VIRAL ETIOLOGY SUBGROUP OF THE PHASE 3 HIMALAYA STUDY OF TREMELIMUMAB PLUS DURVALUMAB IN UNRESECTABLE HEPATOCELLULAR CARCINOMA
Reig, Maria
Tam, Vincent
Sangro, Bruno
Archambeaud, Isabelle
Kelley, Robin Kate
Chan, Stephen
Kudo, Masatoshi
Masi, Gianluca
Paskow, Michael
Makowsky, Mallory
Gupta, Charu
Ran, Di
Negro, Alejandra
Abou-Alfa, Ghassan
HEPATOLOGY, 2024, 80
[29] Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA
Abou-Alfa, Ghassan K.
Chan, Stephen Lam
Kudo, Masatoshi
Lau, George
Kelley, Robin Kate
Furuse, Junji
Sukeepaisarnjaroen, Wattana
Kang, Yoon-Koo
Dao, Tu V.
De Toni, Enrico N.
Rimassa, Lorenza
Breder, Valeriy Vladimirovich
Vasilyev, Alexander
Heurgue, Alexandra
Tam, Vincent
Mody, Kabir
Thungappa, Satheesh Chiradoni
He, Philip
Negro, Alejandra
Sangro, Bruno
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
[30] Low immunogenicity and favorable safety seen with novel regimen of tremelimumab (T) plus durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC)
Kelley, R. K.
Negro, A.
Chen, C.
Ali, S.
Standifer, N.
Watras, M.
Evans, B.
Abou-Alfa, G. K.
ANNALS OF ONCOLOGY, 2020, 31 : S1429 - S1429

← 1 2 3 4 5 →